Search results
Showing 1756 to 1770 of 7682 results
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative
Evidence-based recommendations on PeritX for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites.
Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers
MRI fusion biopsy systems for diagnosing prostate cancer (DG53)
Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer
Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer
Evidence-based recommendations on NIOX MINO, NIOX VERO and NObreath for measuring the amount of exhaled nitric oxide (FeNO) in the breath to help diagnose
Awaiting development [GID-TA10519] Expected publication date: TBC
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]
Awaiting development [GID-TA10909] Expected publication date: TBC
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Suggested remit - To appraise the clinical and cost effectiveness of fingolimod within its marketing authorisation for treating relapsing multiple sclerosis in ...
Awaiting development [GID-TA10346] Expected publication date: TBC
Awaiting development [GID-TA10453] Expected publication date: TBC
In development [GID-TA11035] Expected publication date: TBC
Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]
Suggested remit: To appraise the clinical and cost effectiveness of natalizumab within its marketing authorisation for treating highly active relapsing-remittin...
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]
Awaiting development [GID-HST10022] Expected publication date: TBC
Suggested remit: To appraise the clinical and cost effectiveness of canakinumab within its marketing authorisation for treating Schnitzler syndrome. ...